Modus Therapeutics Holding AB Cash Flow Conversion Efficiency
Modus Therapeutics Holding AB cash flow conversion efficiency. Based on the latest financial reports, Modus Therapeutics Holding AB (MODTX) has a cash flow conversion efficiency ratio of -0.552x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-5.00 Million ≈ $-538.40K USD) by net assets (Skr9.07 Million ≈ $976.18K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Modus Therapeutics Holding AB (2018–2025)
Cash flow conversion efficiency of Modus Therapeutics Holding AB from 2018 to 2025. This chart illustrates how Modus Therapeutics Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Modus Therapeutics Holding AB stock price today for real-time trading data and today's change.
Modus Therapeutics Holding AB Cash Flow Conversion Ratio Explained
Modus Therapeutics Holding AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Modus Therapeutics Holding AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Modus Therapeutics Holding AB ranked by their cash flow conversion efficiency. Also see Modus Therapeutics Holding AB stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Noram Lithium Corp
V:NRM
|
-0.023x |
|
Clear Blue Technologies International Inc
V:CBLU
|
0.094x |
|
Connexa Sports Technologies Inc.
NASDAQ:YYAI
|
0.161x |
|
New Zealand Coastal Seafoods Ltd
AU:NZS
|
-0.786x |
|
Mobico Group Plc
LSE:MCG
|
-1.446x |
|
CCH Holdings Ltd Ordinary Shares
NASDAQ:CCHH
|
N/A |
|
Wellnex Life Ltd
AU:WNX
|
0.154x |
|
Churchill Resources Inc
V:CRI
|
-0.401x |
Annual Cash Flow Conversion Efficiency for Modus Therapeutics Holding AB (2018–2025)
The table below shows the annual cash flow conversion efficiency of Modus Therapeutics Holding AB from 2018 to 2025. Review MODTX free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr9.07 Million ≈ $976.18K |
Skr-18.07 Million ≈ $-1.95 Million |
-1.993x | +71.00% |
| 2024-12-31 | Skr2.14 Million ≈ $229.98K |
Skr-14.68 Million ≈ $-1.58 Million |
-6.870x | -628.09% |
| 2023-12-31 | Skr17.68 Million ≈ $1.90 Million |
Skr-16.68 Million ≈ $-1.80 Million |
-0.944x | -111.23% |
| 2022-12-31 | Skr-2.58 Million ≈ $-278.19K |
Skr-21.72 Million ≈ $-2.34 Million |
8.404x | +922.46% |
| 2021-12-31 | Skr15.73 Million ≈ $1.69 Million |
Skr-16.08 Million ≈ $-1.73 Million |
-1.022x | +1.16% |
| 2020-12-31 | Skr7.00 Million ≈ $752.77K |
Skr-7.23 Million ≈ $-778.17K |
-1.034x | -106.33% |
| 2019-12-31 | Skr-2.69 Million ≈ $-289.06K |
Skr-43.90 Million ≈ $-4.72 Million |
16.343x | +1075.08% |
| 2018-12-31 | Skr23.90 Million ≈ $2.57 Million |
Skr-40.06 Million ≈ $-4.31 Million |
-1.676x | -- |
About Modus Therapeutics Holding AB
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (pu… Read more